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It has been hypothesized that, in aggregate, rare variants in coding regions of genes explain a substantial fraction of the heritability
of common diseases. We sequenced the exomes of 1,000 Danish cases with common forms of type 2 diabetes (including body mass
index > 27.5 kg/m2 and hypertension) and 1,000 healthy controls to an average depth of 563. Our simulations suggest that our study
had the statistical power to detect at least one causal gene (a gene containing causal mutations) if the heritability of these common dis-
eases was explained by rare variants in the coding regions of a limited number of genes. We applied a series of gene-based tests to detect
such susceptibility genes. However, no gene showed a significant association with disease risk after we corrected for the number of genes
analyzed. Thus, we could reject a model for the genetic architecture of type 2 diabetes where rare nonsynonymous variants clustered in a
modest number of genes (fewer than 20) are responsible for the majority of disease risk.Introduction
Twin and segregation studies have suggested that complex
diseases, such as common metabolic disorders, are deter-
mined, in part, by genetic factors.1 As a result, over the
last several decades there has been tremendous interest
in identifying the genetic basis of common diseases.2,3
Recently, researchers have used genome-wide association
studies (GWASs) to identify common variants that increase
risk of common disease. Hundreds of reproducible associa-
tions have been reported between common single SNPs
and particular traits. Some of these associations have
yielded novel biological insights that will be useful for
biomedical research.4
However, it is now well documented that most of the
identified loci have very small effect sizes.5 Despite their
relatively moderate frequency in the population, the com-
mon variants associated with complex traits, to date, can
only account for a small amount of the heritability that
has been estimated for these traits through twin and
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in GWASs and familial studies has been termed the
‘‘missing heritability’’ problem.
Presently, researchers are searching for the missing her-
itability in a number of places.6–8 One such location that
is the subject of much current research is in low-frequency
and rare (frequency < 1%) genetic variants.9,10 Population
genetic theory suggests that if disease-causing variants are
affected by purifying natural selection because they lead
to a slight decrease in reproductive fitness in the individ-
uals carrying them, then a greater proportion of the
heritability will be explained by low-frequency and rare
variants than by common variants.11,12 Furthermore,
low-frequency variants have probably eluded detection
in currently used GWASs. There are two reasons for this.
First, the currently used genotyping arrays are biased
against the inclusion of low-frequency variants. Thus,
many low-frequency variants are never directly tested for
an association with the trait. Second, low-frequency vari-
ants are not tagged by the common variants genotyped
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detection because they are not well correlated with a typed
common SNP.
Although there have been several reported associations
between low-frequency variants and complex traits,13–18
the hypothesis that rare variants account for a large
proportion of the heritability of complex traits remains
to be tested. With the advent of next-generation
sequencing19 and the affordability of exome sequencing,
researchers are gaining the genomic tools with which to
discover and test for associations between rare coding var-
iants and complex disease and directly test the rare-
variant common-disease hypothesis. Such approaches
have recently been successfully applied to the iden-
tification of new mutations responsible for Mendelian
diseases.20–25 Additionally, over the past several years,
advances have been made on the analysis side. The devel-
opment of numerous statistical tests has allowed more
efficient testing for associations between rare variants
within a particular gene and a trait.26–31 Such methods
seek to combine the signal from multiple markers within
a gene to provide greater statistical power than that for
single-marker tests. However, these methods have yet to
be widely applied to exome sequencing data from thou-
sands of individuals. As such, their overall performance
remains to be determined.
One common disease that has been subjected to intense
genetic study is type 2 diabetes.32 The heritability of type 2
diabetes has been estimated to be around 30%.33–35
Through GWASs, 63 loci have been reproducibly associ-
ated with type 2 diabetes.36 However, as for other complex
traits, the associated SNPs can only account for <20% of
the heritability estimated from family studies.36
Here, we seek to evaluate the role that rare coding vari-
ants play in the genetic basis of common forms of type 2
diabetes. We performed a deep whole-exome sequencing
study of 2,000 Danish individuals. We applied both
single-marker and gene-based association tests. Although
we failed to detect any significant association after multi-
ple test corrections, our simulations suggest that our results
are informative about the genetic architecture of type 2
diabetes. In particular, our study suggests that when clus-
tered in a small number of genes, rare coding variants of
moderate to strong effect are unlikely to account for
much of the missing heritability. Rather, if rare coding var-
iants are an important factor in type 2 diabetes risk, they
are most likely scattered across many genes. Our results
have important implications for the design and interpreta-
tion of future medical resequencing studies.Subjects and Methods
Study Populations
We sequenced 2,000 Danish individuals, of which half (the cases)
suffered from type 2 diabetes,37 moderate adiposity (body mass
index [BMI] > 27.5 kg/m2), and hypertension (systolic/diastolic
blood pressure [BP] > 140/90 mmHg or use of antihypertensive
medication). The others were healthy individuals who all hadThe American Joufasting plasma glucose < 5.6 mmol/l, 2-h OGTT-based plasma
glucose < 7.8 mmol/l, BMI < 27.5 kg/m2, and BP < 140/
90 mmHg (and no antihypertensive treatment). Clinical and
biochemical characteristics of the 2,000 individuals involved are
described in Table S1 in the Supplemental Data available with
this article online. The 2,000 sequenced individuals were selected
from three different Danish study populations (Inter99, Steno
samples, and ADDITION [Anglo-Danish-Dutch Study of Intensive
Treatment in People with Screen-Detected Diabetes in Primary
Care]) as previously reported.18
Inter99
The Inter99 cohort is a randomized, nonpharmacological inter-
vention study for the prevention of ischemic heart disease and
was conducted on 6,784 randomly ascertained participants aged
30–60 years at the Research Centre for Prevention and Health
in Glostrup (ClinicalTrials.gov ID NCT00289237). An oral glucose
tolerance test (OGTT) measured plasma glucose and serum insu-
lin at fasting and 30 and 120 min after glucose intake. Subse-
quently, 6,094 participants who were of Danish nationality
and had available DNA were classified as having normal glucose
tolerance (n ¼ 4,525), impaired fasting glycaemia (n ¼ 504),
impaired glucose tolerance (n ¼ 693), screen-detected type 2
diabetes (n ¼ 253), or previously diagnosed type 2 diabetes
(n ¼ 119) according to the World Health Organization (WHO)
1999 criteria. Detailed characteristics of Inter99 have been pub-
lished previously.38,39
Steno
A sample of individuals with clinical-onset type 2 diabetes and a
group of nondiabetic control individuals were ascertained at the
outpatient clinic at Steno Diabetes Center, Copenhagen. An
OGTTwas performed in all control individuals so that individuals
with unknown diabetes or states of prediabetes according toWHO
1999 criteria could be excluded.37
ADDITION
The Danish ADDITION Study is a general-practice type 2 diabetes
high-risk screening and intervention study sampled by the
Department of General Practice at the University of Aarhus
(ClinicalTrials.gov ID NCT00237548).40 The 8,662 Danish partici-
pants with available DNA from the initial screening cohort
included 1,626 participants with screen-detected and untreated
type 2 diabetes and 7,036 nondiabetic subjects. Individuals with
type 2 diabetes were diagnosed by two independent diabetic
plasma glucose values at baseline investigation or at a 1-year
follow-up investigation.
All study participants gave informed consent for use of their bio-
logical samples for genetic studies. The current research protocol
was approved by The Danish National Ethical Committee on
Health Research and is in accordance with the ethical scientific
principles of the Helsinki Declaration II.
Exome Capture and Sequencing
Concentration and quantity of genomic DNAs (gDNAs) were
measured by Qubit Fluorometer (Invitrogen). Agarose gel electro-
phoresis was employed for checking whether gDNAwas degraded.
Only samples without apparent degradation and quality > 3 mg
were retained. DNA from each sample was broken into short frag-
ments ranging from 150 to 200 bp. The resulting fragments were
end repaired, ligated with adaptors, indexed (6 bp), and amplified
by adaptor-mediated PCR (pre-PCR). After purification, the
amplified fragments were hybridized to the SureSelect biotinylated
RNA baits with the Agilent SureSelect All Exon Kit v.2 (with a
46 Mb target region). After a 24 hr hybridization, nonhybridizedrnal of Human Genetics 93, 1072–1086, December 5, 2013 1073
fragments were washed away. The hybridized fragments were
amplified for the production of a sequencing library, which was
sequenced with an Illumina HiSeq 2000 machine. Case and con-
trol samples were randomized and sequenced in index tagged
pools of four (two random cases and two random controls).
Alignment
From the fastq files generated from the Illumina pipeline, all sam-
ples were aligned to the GRCh37/hg19 human reference genome
(UCSC Genome Browser) with the Burrows-Wheeler Aligner
(BWA; v.0.5.8).41 No alternative haplotypes or random chromo-
somes (chromosome parts without a known position) were used.
All reads were mapped to the positive strand of hg19. Duplicate
reads were removed.
Below are the BWA commands used for the alignments to the
GRCH37/hg19 reference genome:
d bwa aln -n 3 -o 1 -e 10 -i 5 -l 32 -t 4 hg19.fa read1.fq -f
read1.sai
d bwa aln -n 3 -o 1 -e 10 -i 5 -l 32 -t 4 hg19.fa read2.fq -f
read2.sai
d bwa sampe -a 2000 hg19.fa read1.sai read2.sai read1.fq
read2.fq j samtools view -C -S –bExtended Target
Sites flanking the target region were also covered by sequencing
reads. Thus, we decided to enlarge the target regions by 100 bp
on each side (termed the ‘‘extended target region’’). Compared
to the original target, which covered only 46,205,397 bp of the
hg19 reference genome, the extended target regions covered
82,207,242 bp.
SNP Discovery and Genotype Calling without
Imputation
For all samples and for every position of the autosomes given by
the extended target region (~82 Mb), we calculated genotype like-
lihoods for all ten possible genotypes by using SAMtools v.0.1.8.42
From the raw likelihoods, we determined the major allele fre-
quency, minor allele frequency (MAF), and maximum likelihood
estimate.43,44 The likelihood was then used for SNP detection.
Specifically, for each site, we estimated the likelihood of the data
under the alternative model by allowing for two alleles (our opti-
mized likelihood) and under a null model in which only one allele
was present. This gave us a likelihood ratio test statistic (LRT) that
was c2 distributed with one degree of freedom and could be con-
verted to a p value. We defined a p value of 106 (LRT > 24) as
our cutoff for putatively variable sites of interest. These analyses
were done with ANGSD (Analysis of Next Generation Sequencing
Data) software.45
On the basis of the genotype likelihoods calculated from
SAMtools, we called genotypes for all 1,998 samples for 2,958,319
sites with a MAF > 0.0001 (1,354,315 in the target regions and
1,604,004 in the extended target regions) by using the approach
devised in Kim et al.,43 where the genotype with the highest likeli-
hood was assigned to each individual. Specifically,
Ghwe ¼ argmaxðg˛f0;1;2gÞ

2
g

f gð1 f Þ2gLðD jG ¼ gÞ

;
where Ghwe is the called genotype for the individual, g is the num-
ber of copies of the minor allele, f is the allele frequency estimated1074 The American Journal of Human Genetics 93, 1072–1086, Deceat that site, and L(DjG ¼ g) is the genotype likelihood from SAM-
tools.Filtering of Sites and Samples
After initial genotype calls, we applied a series of site filters to the
2,958,319 sites with a MAF > 0.0001 to obtain a set of sites with
high-quality genotype calls suitable for association analysis (see
Appendix A). We also filtered individuals for data quality (see
Appendix B).Genotype Calling Using BEAGLE
We used BEAGLE46 to impute genotypes from sequencing data on
2,958,319 sites with an estimated MAF > 0.0001. We performed
BEAGLE imputation with default parameters by using genotype
likelihoods from SAMtools in the following stepwise manner:
1. From our sequencing data, we imputed genotypes for sites
both in the target and extended regions and in the 1000
Genomes project47 (510 kb, at most 15 SNPs) by using
the 1000 Genomes CEU (Utah residents with ancestry
from northern and western Europe from the CEPH collec-
tion) haplotypes as a reference panel (~4.2 million sites).
2. We imputed genotypes from our exome sequencing data
without using a reference panel (2,958,319 sites with an
estimated MAF > 0.0001).
3. We combined the two sets of calls. For sites present in the
1000 Genomes SNP set, we adopted imputed genotypes
from step 1. For sites only present in the exome sequencing
SNP set (not present in 1000 Genomes), we adopted the
imputed genotypes from step 2.
Variable sites were retained if they were successfully imputed
(r2 > 0.2) and if they passed all previously applied filters. Imputed
genotypes were used for association analyses throughout the
paper.Annotation of Putative Variable Sites
The SeattleSeq Annotation 137 server was used for annotation of
all sites. If a variable site was given two or more annotations
because there were different isoforms, themost functional annota-
tion was used. In other words, annotations were ranked as
nonsense > splice > nonsynonymous > synonymous > outside
coding.Validation of Variants
For validation purposes, we performed in-house Sanger sequenc-
ing of all singletons (n ¼ 31) and doubletons (n ¼ 15) identified
via our exome sequencing study in seven genes for maturity-onset
diabetes of the young (MIM 606391) and monogenic obesity. All
gene segments were amplified by standard PCR and directly
sequenced by Sanger sequencing. All primers were designed with
Primer3. The sequences were analyzed on a 3130XL Genetic
Analyzer (Applied Biosystems), and mutations were detected
with SeqScape v.2.5 (Applied Biosystems).Metabolic Gene Sets, Pathways, and Networks
We defined gene sets for monogenic diabetes, obesity, and hyper-
tension, as well as sets of genes identified by GWASs of type 2
diabetes, BMI, and hypertension (see Table S2 for lists of genes
in each set).mber 5, 2013
We next constructed protein-protein interaction networks. To
do this, we selected 76 genes known frommonogenic forms of dia-
betes, obesity, and hypertension or GWAS hits (type 2 diabetes,
obesity, and hypertension) for which the lead association lies
within the protein-coding part of the gene (Table S3).
Protein subnetworks were constructed with the InWeb protein-
protein interaction database v.3.48 InWeb comprises more than
960,000 experimentally derived interactions. We discarded low-
confidence interactions and focused our analysis on a network
consisting of 170,000 high-confidence interactions (defined as
interactions identified in multiple independent studies and
often reported in small-scale experiments rather than in high-
throughput studies). For each gene of interest, we defined protein
subnetworks by the proteins reported to directly interact with the
given gene’s product. To further restrict the analysis to interactions
likely to underlie type 2 diabetes, obesity, or hypertension, we
constructed tissue-specific protein subnetworks by pruning away
proteins whose encoding genes’ mRNA expression levels are below
the median gene expression level of the assigned tissue (Table S3).
We obtained tissue-specific gene expression data from the BioGPS
database49 and manually assigned a single most likely tissue to
each gene of interest.
Association Tests
For single-marker association tests, we applied an allele-based
c2 test (implemented in PLINK50) to test for an association be-
tween case-control status and each of the identified putatively
functional variants (annotated as nonsynonymous, splice-site,
or nonsense SNPs).
Because single-marker tests have suboptimal power to detect
genes with many rare variants affecting the trait,30,51 we also
employed several gene-based tests that combine information
across multiple variants within each gene. Specifically, we applied
the SKAT (Sequence Kernel Association Test),29 KBAC (Kernel-
Based Adaptive Cluster),27 WSS (Weighted Sum Statistic),28 VT
(Variable Threshold),52 Score,31 SSU (Sum of Squared Score),31
SSUw (Weighted Sum of Squared Score),31 and Sum31 tests. SKAT
was implemented with the R package described in Wu et al.29 To
model the relationship between genetic variants and disease status,
we ran SKAT by using both the linear kernel (defined as SKAT1) and
the identity-by-state (IBS) kernel (defined as SKAT2). Additionally,
we ran SKAT with two different weighting schemes. First, we gave
all SNPs equalweight (SKAT1). Second,we used the defaultweights,
which give extra weight to SNPs with lowMAF (SKAT2). In the first
case, SKAT has been shown to be equivalent to the C-alpha test.29
We ran KBAC by using the KBAC R package. To assess significance
for each test, we used 100,000 permutations and the adaptive
approach to increase speed. We ran the WSS method28 by using
the AssotesteR package with 500 permutations to assess signifi-
cance.Only SNPswith aMAF<1%wereused for this test. For genes
with initial p values% 0.002, we ran an additional 50,000 permu-
tations. One gene still had p ¼ 0, so we ran 500,000 permutations
for that gene. We ran the VT method52 by using the AssotesteR
package with 1,000 permutations to assess significance. Only
SNPswith aMAF< 5%were used for this test. For geneswith initial
p values% 0.001, we ran an additional 50,000 permutations. We
ran the other four gene-based tests by using the R code described
in Pan et al.31 We assessed significance by using 1,000 permuta-
tions. For the genes with initial p values equal to 0, we ran an
additional 100,000 permutations. We focus on the SKAT test
throughout much of this paper because it has been shown to
have high statistical power under a variety of conditions.29The American JouAdditionally, all analyses using the gene-based tests were
restricted to include only putatively functional variants, which
we defined to be nonsynonymous, splice-site, or nonsense SNPs.
Three different frequency thresholds for including SNPs were
used: (1) all SNPs regardless of frequency, (2) MAF < 5%, and (3)
MAF < 1%. All analyses described in the paper used the SNPs
with MAF < 5% unless otherwise noted.
It has been suggested that some genes might have too few SNPs
to enable detection of any statistically significant associations.53
Including such genes in the analyses could reduce power by
increasing the number of tests performed and, consequently, the
stringency of the correction for multiple tests. To mitigate this
effect, we only analyzed genes with at least two SNPs meeting
the inclusion criteria described above. For the 5% MAF threshold,
15,133 genes met this criterion, suggesting a Bonferroni-corrected
threshold of 33 106 for a genome-wide 5% significance level. We
also restricted some of the gene-based analyses to only include
genes containing at least five or ten SNPs under a 5% MAF
threshold. A total of 11,347 or 6,105 genes (containing at
least five or ten SNPs, respectively) met these criteria, giving 5%
Bonferroni significance thresholds of 4 3 106 and 8 3 106,
respectively.
Statistical Power Simulations
To assess the power of our exome sequencing study, we per-
formed power simulations. We explored different values of
the total heritability of diabetes risk (on the liability threshold
scale) that could be explained by rare nonsynonymous variants
in a number of genes. We conditioned these simulations on the
observed patterns of genetic variation within our exome
sequencing data and then assigned them effects on the trait
to generate the desired heritability. Although this approach
differs from traditional power simulations, which fix the effect
sizes and allele frequencies without regard to the heritability,
our simulation approach allows a more direct investigation of
the genetic architecture that is compatible with our empirical
results (also see Long and Langley54 for a similar simulation
approach).
We assumed that the total narrow-sense heritability of type 2 dia-
betes risk (h2) is 0.3 (which is likely to be an underestimate33–35,55;
Table S4). We then assumed that this heritability can be divided
among coding variants in n˛f5;10;15;20;50;100;150;200;500g
different risk genes. Under the assumption of n different
genes, the amount of heritability contributed by each gene was
h2n ¼ 0:3=n. We also varied the causal proportion of SNPs within
each gene as c˛f0:25;0:5;1:0g. Within each simulation replicate,
each nonsynonymous SNP with a MAF < 5% had a probability c
of being retained as a causal SNP. If a gene had fewer than 2/c
total SNPs (both causal and noncausal), it was discarded before
the simulation started. This step increased the efficiency of our
simulations by retaining genes that were expected to carry at least
two causal SNPs.
For a given gene sampled fromour data set and values of h2n and c,
we simulated cases and controls by conditioning on the genotypes
in our data. We did this by using the –simu-cc function of the
Genome-wide Complex Trait Analysis (GCTA) package.56 Specif-
ically, for each causal SNP i, we drew the SNP effect, ai, from a stan-
dard normal distribution. LetW denote the normalized genotype
matrix for all 1,965 individuals in the study at the causal SNPs.
Each entry in this matrix is thus wij ¼ xij  2pi=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pið1 piÞ
p
,
where xij ˛{0, 1, 2} is the genotype for the jth individual at the ith
SNP and pi is the allele frequency in our 1,965 individuals.
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Individual quantitative phenotypes were assigned by a standard
linear model,
yj ¼
X
all causal SNPs
wijai þ εj;
where yj is the (quantitative) phenotype of the j
th individual, wij is
the genotype of the jth individual at the ith SNP, ai is the effect of
the ith SNP, and εj is the environmental effect (see below). In
matrix notation, this can be expressed as y¼Wuþ ε. The environ-
mental variance was assigned such that the proportion of the
phenotypic variance attributable to genetic variation was equal
to h2n. Let sG;n be the empirical variance ofWu. Then, the environ-
mental variance for individual j is drawn from a normal distribu-
tion with a mean of 0 and a variance of
sG;n
"
1
h2n
 1
#
:
Intuitively, this takes the genetic variance actually found in the
sample sG;n and then sets the environmental variance such that
h2n ¼
sG;n
sG;n þ sE:
Note that the GCTA approach used the empirical variance of
Wu. Essentially equivalent results can be found with the classic
quantitative genetic equation
sG;n ¼
X
all causal SNPs
2pi

1 pi

a2i :
The 981 individuals with the highest values of ywere considered
to be cases, and the other 984 were the controls.
Our simulations assigned SNP effect sizes such that the observed
patterns of genetic variation explained the desired heritability.
One potential drawback to conditioning on the observed patterns
of variation is that the effect sizes assigned can be unrealistically
large, especially when a given gene (that might only contain a
small number of rare variants) accounts for much of the heritabil-
ity. Thus, we implemented an extra rejection step into our power
simulations. In order to simplify the discussion of the rejection
step, we rescaled the variances so that the total phenotypic vari-
ance equaled 1. We did this by finding the value of C such that
C½sG;n þ sE ¼ 1. Then, we let ki ¼ Cai. In other words, ki was the
normalized SNP effect (still on the liability scale). If ki > 3 for
any SNP within a gene, we rejected that gene and selected a
different one. This procedure increased the probability of
including genes containing either common SNPs (still with a
MAF < 5%) or more SNPs.
The threshold of rejecting genes containing a SNP with ki > 3
was chosen for the following reason. Assume a liability threshold
model (liability follows a normal distribution) in which an indi-
vidual whose liability is >1 has the disease. Further assume that
there is a single causal variant. The liability of individuals who
do not carry the causal variant follows a standard normal distribu-
tion. Thus, roughly 16% of individuals not carrying any risk vari-
ants would have the disease. Under the assumption that a single
causal SNP i has an effect ki ¼ 3 (the cutoff we used) per allele
copy on the liability scale, the liability of heterozygous individuals
would be normally distributed with a mean equal to 3. Then,
97.8% of individuals who carry the causal SNP as a heterozygote
would have the disease (i.e., have a risk score > 1). Thus, the risk
variant is almost fully penetrant, and further increasing ki would1076 The American Journal of Human Genetics 93, 1072–1086, Decenot substantially increase the penetrance of the risk allele. Thus,
requiring SNPs to have ki < 3 is biologically reasonable and was
the upper bound on the effect size used in our power simulation.
We then ran SKAT and KBAC on the simulated phenotypes and
the actual genotypes and recorded the p values. This process
was repeated until we had 1,000 simulation replicates for each
combination of values of n and c. The proportion of simulation
replicates with p values less than the specified significance level
was the power of the test.
The simulations described above evaluate the SKAT test’s power
to detect a single association. But, under the polygenic models of
disease risk, there are many genes (n of them) that contribute to
disease risk. Although the effect of an individual gene under this
model becomes smaller, making the gene harder to detect, there
aremore opportunities to detect a truly associated gene. Therefore,
we also evaluated the power to detect at least one associated gene
at our Bonferroni significance threshold. The power to detect at
least one gene was calculated as PðdetectRone geneÞ ¼ 1 bn,
where b is the type II error, or the proportion of simulation repli-
cates that were not significant under our Bonferroni threshold,
and n is the number of risk genes in the particular model.Results
Description of Variants Found and Data Quality
The fraction of the target region covered by various depths
is shown in Figure S1. The median and mean depth of
coverage were 463 and 56.33, respectively. The exome
coverage (the percent of targeted bases that were covered
by at least one read) ranged from 94.11% to 98.76%. The
average exome coverage per sample was 97.27% (SD ¼
0.00595; Figure S2). No sample had less than 90% of its
exome covered.
For general quality assessment of the sequencing, we
used nonimputed genotype calls for the 729,538 variants
identified and retained after site filtering and application
of the LRT score > 24 (Appendix A). The majority of
variants present in the data set had a low minor allele
count, as expected. There were no general differences
between cases and controls in the frequency patterns
(Figure S3). Additionally, we found no bias in the transi-
tion-to-transversion (Ti/Tv) ratios for different bins of
minor allele counts (Figure S4), total depth (Figure S5), or
LRT statistics (Figure S6). Furthermore, we found few
differences in the Ti/Tv ratios, average total depths, and
average LRT scores between rare SNPs (minor allele
count < 10) absent from and those already present in
dbSNP v.134 (Table S5).
As expected, the minor allele count differed across anno-
tation classes in that functional variants had lower MAFs
(Figure S7). We also stratified the Ti/Tv ratios into different
annotation classes, both for all individuals and for cases
and controls separately (Table S6). In some annotations,
we detected a slight decrease in the Ti/Tv ratio in cases
compared to in controls. However, the Ti/Tv ratios for
the different annotation categories were generally in
proximity to what others have reported.53 These findings
suggest that the data are of sufficient quality.mber 5, 2013
Figure 1. Q-Q Plots Showing the p Values from the SKAT and
KBAC Association Tests
(A) SKAT1 test (linear kernel, all variants have equal weight).
(B) SKAT2 test (weighted IBS kernel, extra weight to rare variants).
(C) KBAC test.
Solid lines denote the diagonal.As discussed in the Subjects and Methods, we extended
the target regions by 100 bp. The extended target regions
showed a lower median depth of coverage than did the
actual target regions (Figure S8). Also, the extended target
regions showed a lower Ti/Tv ratio than did the targetThe American Jouregions. This was because variants outside of the coding
region were included in the extended region (Table S7).
However, the ratio was still within the expected
threshold.57 The majority of variants in the extended re-
gion were noncoding, but we also found approximately
2,500 additional variants annotated to the exonic regions
(Table S8).
To test for potential bias in the BEAGLE data set, we
calculated the Ti/Tv ratio for each sample (Figure S9). We
observed no outlying samples. We also plotted the Ti/Tv
ratio as a function of r2 (Figure S10) and found that as r2
increased, the Ti/Tv ratio stabilized around 2.5. Finally, as
seen in the unimputed data, putatively functional variants
were present at a lower frequency than were other variants
(Figure S11).
Figure S12 shows the distribution of the number of sites
across the exome where each individual carries at least one
nonreference allele for different types of coding SNPs.
Figure S13 shows the number of nonreference alleles
carried by each exome for different types of coding SNPs.
These counts are broadly in line with what has been
previously reported from exome sequencing data.53,58,59
We also attempted to validate some of the singletons and
doubletons detected in our data set. All 31 singletons were
validated by traditional Sanger sequencing. For one of the
15 doubletons, we could only validate one carrier of the
variant; the other 14 doubletons were validated for both
carriers.
After genotype imputation and quality-control analyses,
we were left with 1.6 million autosomal variants (of which
286,083 were in the exons). See Table S9 for the number of
SNPs per gene.
Results of the Association Tests
We next applied the gene-based association tests to our
exome sequencing data. The quantile-quantile (Q-Q) plots
of the p values from the SKAT and KBAC association tests
showed good agreement with the expected distribution,
suggesting few biases (e.g., population stratification,
differences in technical artifacts, etc.) between cases and
controls (Figure 1). However, none of the genes under
either test passed the Bonferroni-correction threshold
(Tables S10–S12). We obtained similar results when we
only included SNPs with a MAF < 1%, when we included
all SNPs regardless of frequency, and for the additional
six gene-based association tests (Figures S14–S18 and Ta-
bles S10–S18). Additionally, we found no genes passing
the Bonferroni-correction threshold when we reduced
the number of genes analyzed to include only those with
at least five or at least ten SNPs (Figures S19 and S20).
We also applied a single-marker association test to each
of the putative functional variants. However, no SNP
passed the Bonferroni-correction threshold of p < 107
(Figure S21 and Tables S19–S21). Interestingly, there was
a substantial overlap in the top genes identified in the
single-marker analysis and the SKAT association tests. For
example, 9 of the top 20 genes with the lowest p valuesrnal of Human Genetics 93, 1072–1086, December 5, 2013 1077
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Figure 2. Power to Detect an Association with SKAT or KBAC for
Different Numbers of Causal Genes
Different colored curves denote different significance levels. The
Bonferroni threshold was 33 106. Note that power was low when
there were many causal genes (genes containing causal variants)
such that the heritability explained by a given gene was very low.
(A) SKAT1 test (linear kernel, all variants have equal weight).
(B) SKAT2 test (weighted IBS kernel, extra weight to rare variants).
(C) KBAC test.in the SKAT1 test were also among the top 20 genes with
the lowest single-marker p values. This finding suggests
that in our data, the effects detected with the SKAT test1078 The American Journal of Human Genetics 93, 1072–1086, Dececould also be captured by the single-marker analysis. How-
ever, this pattern is not universal to all association tests,
or data sets, given that only three genes with the lowest
p values in the KBAC test in our data were among the
top 20 genes with the lowest single-marker p values.
Further investigation of the relationship between single-
marker and gene-based association tests is warranted.
Gene-Set Analyses
Sets of genes related to diabetes or metabolic traits might
be enriched with lower p values from the gene-based asso-
ciation tests, even though none of the individual p values
passed the multiple test correction. We examined several
sets of genes related to metabolism, as well as the corre-
sponding interactomes of a subset of these genes (Tables
S2 and S3). We found that genes previously associated
with obesity through GWASs were enriched with lower
SKAT1 p values (p < 0.006, Table S22). Additionally, a few
of the interactomes, including those for two genes in
which mutations are known to cause monogenic forms
of diabetes60 (HNF1A [MIM 142410] and HNF4A [MIM
600281]), were marginally enriched with putatively func-
tional variants relative to synonymous variants. However,
these results were not significant after correction for
multiple tests (Table S23). A comprehensive overview of
the gene-set analysis is found in Tables S23 and S24.
Finally, monogenic forms of diabetes might be hidden
among individuals diagnosed with type 2 diabetes. We
therefore examined whether any of the individuals in
our study carried mutations previously demonstrated to
cause diabetes in the most common monogenic-diabetes-
associated genes (HNF1A [MIM 142410], GCK [MIM
138079], and HNF4A [MIM 600281]). We identified three
carriers of HNF1A mutations (two cases and one control)
and two carriers of GCK mutations (two cases).60,61
Statistical Power of the Gene-Based Association Tests
To evaluate the statistical power of these tests in the
context of our study under a variety of genetic models,
we performed a series of power simulations. These simula-
tions conditioned on the number of SNPs per gene and the
genotypes of the individuals sequenced in our study. As
such, they should closely reflect the power of our study.
These models assumed that the total heritability of type
2 diabetes (approximately 30%33–35,55) is equally divided
among a number (n) of different genes, each accounting
for 1/nth of the heritability. As expected, the power to
detect an association depended on the amount of heritabil-
ity explained and the number of causal variants (Figure 2).
For example, if all of the heritability of the trait is ex-
plained by functional variation at five genes, we would
detect a given causal gene (a gene containing causal muta-
tions) by using the SKAT1 test at our Bonferroni threshold
70% of the time. As the amount of the heritability ex-
plained by a given gene in our simulations decreased, so
did the power to detect that association. When there
were more than 15 genes contributing risk, the power tomber 5, 2013
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Figure 3. Power to Detect at Least One of n Causal Genes at
a Bonferroni Significance Threshold for Different Numbers of
Causal Genes
The power to detect at least one causal gene is calculated as 1 
(1  power)n, where n is the number of causal genes and power
is estimated from the simulations shown in Figure 2.detect an association at a given gene was extremely low
(<10% with the Bonferroni threshold), suggesting that
we did not have power to detect genes of weak effect
with the present sample size. Similar results were obtained
for the SKAT2 and KBAC tests, although KBAC showed
lower power than the SKAT tests for the parameters simu-
lated here (Figure 2). We also varied the proportion of
SNPs assumed to be causal (c) within a gene. As c decreased,
power also slightly decreased (Figures S22–S24). Our power
simulations conditioned on including genes for which the
individual normalized SNP effects ðkiÞ were <3. The simu-
lations not including this conditioning step suggest that
our study had lower power than described (Figure S25).
This apparent decrease in power was a result of including
genes with very little genetic variation and very large ki
values. As discussed in the Subjects and Methods section,
including genes with SNPs whose ki > 3 is not biologically
reasonable. Thus, further results only include genes in
which all SNPs have ki < 3.
The simulations described above estimated the power
to detect a single associated gene. However, applying
them to the entire exome provides the possibility of detect-
ing an association at any of the n different risk loci. We
next tabulated the probability of detecting at least one
significantly associated gene (at the Bonferroni threshold)
for each of the genetic models analyzed (see Subjects and
Methods). Models withmany risk genes have smaller effect
sizes per gene, making it harder to detect each gene.
However, as the number of risk genes increases, there are
more opportunities to detect a causal gene, increasing
the probability of detecting at least one true association
(Figure 3). The power to detect at least one significantThe American Jougene was highest (>80%) for the SKAT tests when there
were a limited number of risk genes (fewer than 15). At
20 risk genes, we had >60% power to detect at least one
risk gene by using the SKAT test (Figure 3). As the number
of risk loci increased beyond 20, the amount of the herita-
bility explained by any one gene was so low that we had
limited power to find even one such gene. The overall
trend held regardless of the proportion of nonsynonymous
SNPs assumed to be causal (c) within each gene. Although
the power to detect at least one significant gene decreased
as c decreased, we still had >50% power to detect at least
one gene even when c ¼ 0.25 and there were %20 causal
genes (Figure S26).
In sum, the statistical power analyses suggest that we
had limited power to detect a particular association unless
the gene in question explained a substantial proportion
of the heritability of disease risk; however, when we
applied the simulations to the whole exome, we had sub-
stantial power to detect at least one significant association
at our Bonferroni threshold if rare variation in a modest
number of genes (fewer than 20) was responsible for the
majority of disease risk. Because we did not detect such
an association, our results suggest that low-frequency
variants in a modest number of genes do not explain a
substantial amount of the heritability of type 2 diabetes.Discussion
It has been hypothesized that rare genetic variants with
moderate effects on disease risk could account for much
of the missing heritability of complex traits.6,9,10,62 We
have taken a first step toward testing this hypothesis for
type 2 diabetes. We did not detect any significant asso-
ciations between rare coding variants and common forms
of diabetes. Our study was underpowered to detect weak
genetic effects, but if much of the heritability of type 2
diabetes is explained by variants in a modest number of
genes, we should have detected at least one associated
locus at our Bonferroni significance threshold. Thus, our
empirical results, combined with the statistical power
simulations, suggest that when clustered in fewer than
20 genes, coding variants of moderate effect do not
account for much of the missing heritability of a common
polygenic disorder such as type 2 diabetes.
Importantly, although GWASs have identified more
than 60 common SNPs associated with type 2 diabetes
risk,36 these data alone are insufficient to reject a model
where fewer than 20 genes containing variants of strong
effect can account for much of the heritability of the
disorder. The reason that GWAS data alone cannot be
used for rejecting this model is that all the loci implicated
through GWASs have very weak genetic effects and only
explain a small fraction of the total heritability of the
trait.36 Thus, there is still a tremendous amount of
heritability to be explained. GWASs of common variants
do not address the question of whether that heritabilityrnal of Human Genetics 93, 1072–1086, December 5, 2013 1079
could be accounted for by low-frequency and rare variants
of moderate effect in a small number of genes. Our whole-
exome sequencing study has explicitly addressed this
question. Additionally, we did not examine whether there
are fewer than 20 genes involved in type 2 diabetes but
rather looked at whether rare coding variants in fewer
than 20 genes account for much of the heritability. In
such a model, any number of other genes that do not
account for much of the heritability can be involved.
The previously identified GWAS loci would fall into this
category.
In our statistical power simulations, we assumed that
each of the n risk genes account for the same proportion
of the heritability. Both theory and data from common
variants suggest that this is unlikely to apply in prac-
tice.5,63–65 However, the assumption that n distinct genes
contribute to the heritability equally is actually conserva-
tive and means that we can reject additional models that
we did not explicitly simulate. For example, imagine a
type 2 diabetes architecture in which 10 of 100 risk loci ac-
count for almost all of the heritability. Although we did
not directly simulate this scenario, it would be very similar
to our simulation in which ten genes explained all of the
heritability of type 2 diabetes. The reason for this is that
the remaining 90 genes of weak effect would most likely
have failed to be detected in our study. If they collectively
do not account for much of the heritability, then they
can be discounted in our simulations, and this scenario
becomes equivalent to one that we simulated (i.e., the
scenario with ten causal genes).
Our power simulations included several important
assumptions. First, we assumed that causal variants act in
an additive manner. Although such a model is predicted
from theory and data,66 it is not clear howwell the additive
model will hold for rare coding mutations. If many rare
coding mutations are weakly deleterious and are affected
by purifying natural selection, they might be slightly
recessive.67,68 Second, we assumed that simulated causal
variants can either increase or decrease diabetes risk. Third,
we assumed a heritability of 30% for the trait. If the true
heritability of common forms of type 2 diabetes is lower,
then our power to detect an association in our study simi-
larly would have been lower. However, published estimates
of the heritability of type 2 diabetes and related metabolic
traits suggest that 30% is toward the low end of the herita-
bility estimates for these phenotypes (Table S4). For this
reason, we did not further decrease the heritability used
in our power simulations to account for the small (5.7%)
variance in disease risk that can be accounted for by
the 63 previously identified associations with common
variants.
Our empirical and simulation results are compatible
with a variety of different genetic architectures for type
2 diabetes. First, if rare coding variants are responsible
for the majority of the heritability of the trait, the variants
are most likely scattered across many (>20) different
genes. Thus, genetic variants in no one gene can account1080 The American Journal of Human Genetics 93, 1072–1086, Decefor much of the heritability of the trait. Biologically, such
a model would postulate that there are a large number of
genes that can be mutated to cause type 2 diabetes in a
given individual. Each individual would then carry a sub-
set of genetic variants located in several of the many
causal genes. Our finding that genes previously impli-
cated in obesity risk through GWASs showed unusually
low SKAT p values in our study supports a scenario in
which low-frequency and rare variants in multiple genes
could be responsible for risk of common metabolic dis-
eases. It also suggests that genes carrying common vari-
ants associated with a trait could also carry additional
low-frequency and rare coding variants that increase dis-
ease risk.
Yet another model for the genetic architecture of dia-
betes that could explain our results is that low-frequency
and rare coding variants do not account for much of the
heritability of type 2 diabetes. Under this scenario, the
missing heritability could be located in common or
low-frequency and rare variants in noncoding regions
of the genome. Recent studies that jointly modeled dia-
betes or obesity risk as a function of genetic relatedness
across all of the GWAS SNPs have suggested that much
of the heritability of these traits can be explained by
common variants with effects that are too small to
reach genome-wide significance in currently used
GWASs.69–71 Under this model, low-frequency and rare
coding variants do not account for a substantial amount
of the heritability of complex traits. Our results are consis-
tent with such a model. Alternatively, the heritability of
type 2 diabetes could have been overestimated in family
studies as a result of environmental factors or gene-gene
interactions.72
Recently, is has been suggested that when clustered
within the same gene, rare variants of strong effect could
explain some of the associations between common vari-
ants found in GWASs and complex traits.73,74 Such signals
have been termed ‘‘synthetic associations.’’ We found little
evidence for such synthetic associations within our data.
In particular, we did not detect an excess of functional
variants within genes containing common variant(s)
implicated in diabetes, obesity, or hypertension through
GWASs. Such an excess could be expected under a model
where the original GWAS signal could be explained by
rare functional variants. Additionally, we found that genes
containing GWAS hits for obesity had significantly lower
SKAT1 p values than did random genes. Although this
pattern could be driven by synthetic associations, we
found that the SKAT1 p values were weakly correlated
(Spearman’s r ¼ 0:34, p ¼ 0.067) with the best single-
marker p value within each gene. The fact that the sin-
gle-marker p values were even slightly informative
regarding the multimarker SKAT1 p values suggests that
the skew in SKAT1 p values was not entirely driven by
very rare variants (e.g., singletons in cases), as predicted
by the synthetic-association hypothesis. However, further
investigations using larger numbers of cases and controlsmber 5, 2013
will be required for convincingly supporting or rejecting
the synthetic association hypothesis.
The fact that we did not detect any significant asso-
ciation in our data has implications for designing and
analyzing further sequencing studies for elucidating the
genetic basis of complex traits. If there is substantial locus
heterogeneity, then gene-based tests of association are
likely to be severely underpowered. The reason for this
is that a particular causal gene is likely to carry causal var-
iants in only a small number of the affected cases. Other
cases carry risk variants in different genes. The gene-based
association tests currently used are substantially under-
powered in this model, even with sample sizes of thou-
sands of cases and controls. If the many distinct genes
that, if mutated, could give rise to the trait of interest all
cluster within a small number of pathways, power could
be gained through the implementation of the gene-based
tests at a pathway level. Another possibility would be to
use family-based association studies of rare variants on
extended pedigrees.75,76 This approach could be particu-
larly effective if the same causal genes are responsible
for the phenotype for most members of the pedigree.
Further methodological work is required in this area.
Conversely, if rare variation in coding regions contributes
little to complex disease risk, then this would argue for
alternative study designs. For example, whole-genome
sequencing, rather than exome sequencing, would allow
for the detection of rare variants outside of the coding re-
gions. This would be an effective strategy if the missing
heritability could be accounted for by rare noncoding
regulatory variants.
Although our results argue that low-frequency and
rare coding variants in a modest number of genes do
not account for the majority of the heritability of
common forms of type 2 diabetes, it is not clear how
generalizable this result is to other complex traits. Several
other exome sequencing studies have failed to detect any
significant associations between low-frequency variants
and schizophrenia,77 epilepsy,78 autism,79 or autoimmune
diseases.80 However, recent studies have associated rare
variants with age-related macular degeneration.81–83
Thus, the genetic architecture and the role of low-fre-
quency and rare variants are likely to be trait dependent
and will need to be addressed empirically.Appendix A: Filtering Sites
After generating initial genotype calls from SAMtools, we
applied a series of site filters to the 2,958,319 sites with a
MAF > 0.0001 to obtain a set of sites with high-quality
genotype calls suitable for association analysis. We
describe those filters here:Depth Filter
The average depth per site across all 1,998 samples was
calculated from pile-up files generated by SAMtools. SitesThe American Jouwith an average depth less than 4 or greater than 150
were removed.Base-Quality-Score Filter
For each site, we tested whether base quality scores of the
minor allele were significantly smaller than those from
the major allele. Base quality scores were collected for the
major and minor alleles. Because the combined quality
scores were always very large, even sites that only had a
small difference between the median quality scores for
both alleles gave very significant Wilcoxon rank-sum
p values. To set up a proper filter, we defined a quantity
Qdiff ¼ jm1 m2j=0:5ðm1 þm2Þ, which measured the
absolute difference in read quality scores between the
major allele and the minor allele. Here, m1 is the median
read quality score for the major allele, and m2 is the
median read quality score for minor allele. Sites with
a Wilcoxon rank-sum p value < 107 and Qdiff > 0.1 were
removed.Strand-Bias Filter
Because the capture experiment shows biases with respect
to strand, it is inappropriate to test the hypothesis that
half of the reads were derived from the forward strand
and the other half were derived from the reverse strand.
From the pile-up files generated by SAMtools, we tested
the homogeneity of the distribution of reads along the
two strands for the major and minor alleles. We first
made a 2 3 2 table whose rows contained the major (M)
and minor (m) alleles and whose columns contained the
number of reads that came from the forward strand (þ)
and the number of reads from the reverse strand (). The
odds ratio (OR), defined as (Mþ / M) / (mþ / m), was
used formeasuring the difference of the strand distribution
for reads from the major allele and reads from the minor
allele. The p values were calculated with a Fisher’s
exact test. Sites with p values < 107 and log2 (OR) less
than 3 or greater than 3 were removed.Mappability Filter
We computed amappability score to assess the accessibility
of each base in the human genome under typical Illumina
sequencing conditions. The mappability score represents
the probability that a read comes from the hg19 genomic
position to which it mapped. As a probability, the mapp-
ability score ranges from 0 to 1. Sites with mappability
scores < 0.5 were removed.Homopolymer Filter
The homopolymer run is the length of the homopolymer
surrounding a SNP site. For example, on hg19, the
10-base sequence on either side of site chr1: 14,673 is
50-CTGGGTCTGG[G]GGGGAAGGTG-30. The maximum
homopolymer run of the SNP site (denoted by [G]) is
7. Sites with homopolymer runs greater than 6 were
removed.rnal of Human Genetics 93, 1072–1086, December 5, 2013 1081
Allele-Balance Filter
At well-behaved heterozygous sites, within a given indi-
vidual, the number of reads for the major allele should
equal the number for the minor allele. We tested this by
using a binomial test with p ¼ 0.5. Specifically, from the
SAMtools pile-up files, we calculated the total number
of reads for the major allele and the minor allele at all
heterozygous genotype calls. We calculated the absolute
difference in the number of reads for the major and
minor alleles as Bdiff ¼ jr1  r2j=jr1 þ r2j, where r1 is the
number of reads for the major allele and r2 is the number
of reads for the minor allele. Sites with p values < 106
and Bdiff > 0.5 were removed.Hardy-Weinberg Filter
The Hardy-Weinberg filter was applied after genotype
calling (estimated from the 1,000 control samples). The
exact test11 was applied with the software PLINK.12
SNPs with p values < 106 were removed. After applica-
tion of the above quality threshold, 729,538 (713,122
autosomal) variants (of which 282,823 were in the exonic
region) were retained for further analyses.Appendix B: Filtering Individuals
Low Sequencing Depth
In total, 1,998 samples were successfully sequenced. Of
these, 999 were male and the remaining 999 were female.
After removal of duplicated reads, the average depth of
each sample was 563 (SD ¼ 8.71). With the exception of
one sample with an average depth of 253, all samples
were sequenced to a depth R 303, and 1,522 (76.2%)
samples were sequenced to a depth R 503. The sample
with a depth of 253 was removed.Contamination
In the process of library construction and DNA
sequencing, a sample could become contaminated. For
a heavily contaminated sample, more variants will be
identified and more heterozygous genotypes will be called.
But for a sample that is only slightly contaminated, we
might not observe such a deviation. For two samples
(A and B), let Ai and Bi be the genotypes at a variable site
i. Ai and Bi can take valuesMM,Mm, ormm, corresponding
to a homozygote for the reference allele, a heterozygote,
and a homozygote for the nonreference allele, respectively.
If sample A is contaminated by B and Ai isMM and Bi ismm
orMm, for a sequencing read, we have a higher probability
to observe an m than in the situation when A is not
contaminated. Given a sample that has been genotyped
at thousands or more variable sites across the autosomes,
we can calculate the fraction of reads that disagree with
known genotypes at homozygous sites. Samples that
show a large deviation are most likely contaminated. In
practice, we applied the above method to 1,963 samples
with Iselect data.13 We did calculations at 7,219 variable1082 The American Journal of Human Genetics 93, 1072–1086, Decesites with aMAF> 0.05 in unique regions of 22 autosomes.
Reads that disagreed with known homozygous genotypes
were counted. SNP sites with sequencing depth < 83
were skipped. We found six samples showing obvious
deviations, indicating that they were contaminated. These
samples were excluded from further analyses.Sex Check, Inbreeding, Relatedness, and Concordance
with Previous Genotype Projects
We used PLINK to check for correct sex, inbreeding, and
relatedness. Five samples were removed because of F-values
(inbreeding coefficients) lower than 0.12 (indicating
contamination, admixture, or genotyping errors) or higher
than 0.12 (indicating inbreeding). Eight samples had
disagreements between the genotypic and phenotypic
sex or had undetermined genotypic sex.
We assessed the concordance with previous genotyping
projects by comparing genotype data from previous
projects to our exome sequencing data. The number of
overlapping SNPs from previous genotyping and exome
sequencing was 65. Eighteen samples had missing geno-
types for all sites and could thus not be compared. Three
samples had a genotype concordance < 0.9. These samples
were excluded.
We found two pairs of duplicate samples. One was part
of a parent-offspring pair. We also found seven pairs of
full siblings and three pairs with second-degree relation-
ships (half siblings). To extract the half siblings, we first
removed IDs with too high or low inbreeding coefficient
(five individuals, described above). When two samples
were found to be related, we removed one of them from
our analyses.
After application of the above filters, 1,965 samples (983
controls and 982 cases) were retained for further analyses.Supplemental Data
Supplemental Data include 26 figures and 24 tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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